65,057 Shares in Boston Scientific Corporation $BSX Bought by Spartan Wealth Advisory Services LLC

Spartan Wealth Advisory Services LLC acquired a new position in Boston Scientific Corporation (NYSE:BSX) in the first quarter, HoldingsChannel reports. The institutional investor acquired 65,057 shares of the medical equipment provider’s stock, valued at approximately $4,082,000.

Several other institutional investors have also recently added to or reduced their stakes in the business. IMA Advisory Services Inc. grew its position in shares of Boston Scientific by 6.7% during the 1st quarter. IMA Advisory Services Inc. now owns 20,484 shares of the medical equipment provider’s stock valued at $1,285,000 after buying an additional 1,278 shares during the last quarter. GS Investments Inc. bought a new position in Boston Scientific in the first quarter worth about $613,000. Gryphon Financial Partners LLC boosted its stake in Boston Scientific by 5.2% in the first quarter. Gryphon Financial Partners LLC now owns 12,139 shares of the medical equipment provider’s stock valued at $762,000 after acquiring an additional 599 shares during the period. Assetmark Inc. boosted its stake in Boston Scientific by 36.9% in the first quarter. Assetmark Inc. now owns 145,679 shares of the medical equipment provider’s stock valued at $9,141,000 after acquiring an additional 39,270 shares during the period. Finally, Angeles Wealth Management LLC grew its holdings in shares of Boston Scientific by 11.2% during the first quarter. Angeles Wealth Management LLC now owns 7,149 shares of the medical equipment provider’s stock valued at $449,000 after purchasing an additional 721 shares during the last quarter. Institutional investors own 89.07% of the company’s stock.

Insiders Place Their Bets

In related news, Director Edward J. Ludwig acquired 3,580 shares of the business’s stock in a transaction that occurred on Wednesday, May 20th. The shares were acquired at an average cost of $56.68 per share, for a total transaction of $202,914.40. Following the completion of the purchase, the director directly owned 25,359 shares in the company, valued at $1,437,348.12. This trade represents a 16.44% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director David C. Habiger acquired 2,250 shares of Boston Scientific stock in a transaction that occurred on Wednesday, May 20th. The stock was bought at an average cost of $55.92 per share, with a total value of $125,820.00. Following the acquisition, the director directly owned 13,878 shares of the company’s stock, valued at approximately $776,057.76. This trade represents a 19.35% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. In the last quarter, insiders acquired 9,800 shares of company stock worth $554,012. 0.34% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on BSX shares. Raymond James Financial reiterated an “outperform” rating and set a $88.00 price target (down from $97.00) on shares of Boston Scientific in a research report on Monday, March 30th. Leerink Partners reduced their price objective on Boston Scientific from $87.00 to $74.00 and set an “outperform” rating for the company in a research report on Thursday, May 28th. Wolfe Research downgraded Boston Scientific from an “outperform” rating to a “peer perform” rating in a research note on Friday, May 29th. The Goldman Sachs Group set a $71.00 target price on Boston Scientific in a research report on Thursday, May 28th. Finally, Piper Sandler reiterated an “overweight” rating and issued a $65.00 target price on shares of Boston Scientific in a research note on Friday, June 12th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating, four have assigned a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $79.84.

Boston Scientific Stock Performance

BSX opened at $43.95 on Friday. The business’s 50 day moving average is $48.18 and its 200-day moving average is $65.87. The stock has a market cap of $65.33 billion, a PE ratio of 18.39, a price-to-earnings-growth ratio of 0.84 and a beta of 0.58. The company has a current ratio of 1.90, a quick ratio of 1.22 and a debt-to-equity ratio of 0.42. Boston Scientific Corporation has a twelve month low of $42.20 and a twelve month high of $109.50.

Boston Scientific (NYSE:BSX) last issued its quarterly earnings data on Wednesday, April 22nd. The medical equipment provider reported $0.80 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.79 by $0.01. Boston Scientific had a return on equity of 19.17% and a net margin of 17.29%.The business had revenue of $5.20 billion during the quarter, compared to analyst estimates of $5.19 billion. During the same period in the prior year, the company posted $0.75 EPS. The business’s revenue for the quarter was up 11.6% compared to the same quarter last year. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. On average, analysts predict that Boston Scientific Corporation will post 3.35 earnings per share for the current year.

Boston Scientific announced that its board has approved a share repurchase program on Monday, May 18th that authorizes the company to buyback $5.00 billion in outstanding shares. This buyback authorization authorizes the medical equipment provider to repurchase up to 6.4% of its stock through open market purchases. Stock buyback programs are often a sign that the company’s management believes its shares are undervalued.

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.